---
layout: post
title: "康弘药业：康柏西普眼用注射液获批增加适应症"
date: 2022-05-09 12:04:24 +0800
categories: jiemianxinwen
tags: 界面新闻新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002773" data-code="002773|0|2" data-code2="002773|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002773&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002773_0" data-code="K 002773|0|2" data-code2="K 002773|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>康弘药业5月9日午间公告，全资子公司康弘生物收到国家药品监督管理局签发的关于康柏西普眼用注射液增加适应症“继发于视网膜静脉阻塞(RVO)(视网膜分支静脉阻塞(BRVO)或视网膜中央静脉阻塞(CRVO))的黄斑水肿引起的视力损伤”的《药品注册证书》。<br /></p><p class="em_media">（文章来源：界面新闻）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202205092372445987>

[返回界面新闻新闻](//finews.withounder.com/category/jiemianxinwen.html)｜[返回首页](//finews.withounder.com/)